Identification of a novel methicillin-resistant Staphylococcus aureus epidemic clone in Córdoba, Argentina, involved in nosocomial infections.

Journal of Clinical Microbiology
Claudia SolaCordoba MRSA Collaborative Study Group

Abstract

Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are increasingly a main health concern worldwide for hospitalized patients. In addition, the prevalence of community-acquired infection has risen continuously during the last few years. Some MRSA clones spread easier than others within the hospital environment and therefore are frequently implicated in outbreaks. Thus, the spread of a unique epidemic multiresistant clone, the so-called South American clone, is the main cause of nosocomial infections produced by this bacterium in Brazil and in some regions of Argentina, Chile, and Uruguay. In the present work we describe the identification of a novel clone of MRSA that is involved in nosocomial infections and that shows a prevalence as high as that for the South American clone. A total of 53 consecutive single-patient MRSA isolates were recovered during a 3-month period (May to July 1999) from six different hospitals (955 beds) in Córdoba. The isolates were initially typed according the antibiotic resistance and phage susceptibility patterns, followed by genotyping using pulsed-field gel electrophoresis (PFGE). PFGE analysis of the 53 MRSA isolates revealed six major types (A to F) and 25 subtypes. The B-typ...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Jan 1, 1986·Antimicrobial Agents and Chemotherapy·B J Hartman, A Tomasz
Aug 1, 1987·Journal of Clinical Pathology·J I Roberts, M A Gaston
Sep 1, 1995·Journal of Clinical Microbiology·L A TeixeiraA Tomasz
May 1, 1994·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·H S SaderR N Jones
Feb 1, 1994·Journal of Clinical Microbiology·F C TenoverR Hollis
Jul 1, 1994·Journal of Clinical Microbiology·D J GehaD H Persing
Jan 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H de LencastreA Tomasz
Jan 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M PujolF Gudiol
Feb 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P T TassiosN J Legakis
Oct 1, 1996·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·M Aires de SousaH de Lencastre
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Jul 3, 1998·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·R MatoH de Lencastre
Aug 15, 1998·Journal of Clinical Microbiology·M Aires de SousaH de Lencastre
Oct 23, 1998·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·H Peltroche-LlacsahuangaR Lütticken
Nov 18, 1998·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·R B RobertsB N Kreiswirth
Feb 13, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A CorsoH de Lencastre
Mar 26, 1999·Diagnostic Microbiology and Infectious Disease·R L Nichols, I I Raad
Feb 8, 2000·The Journal of Antimicrobial Chemotherapy·N WoodfordH M Aucken
Feb 12, 2000·Journal of Medical Microbiology·M V Da Silva CoimbraA M Figueiredo
Mar 18, 2000·Journal of Chemotherapy·A P Wilson
Apr 4, 2000·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S SalmenlinnaJ Vuopio-Varkila
Jan 6, 2001·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A van Belkum
Jan 6, 2001·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·D J DiekemaUNKNOWN Sentry Participants Group
May 29, 2001·Journal of Clinical Microbiology·M Aires De SousaH de Lencastre
Sep 1, 1952·The Journal of Hygiene·R E O WILLIAMS, J E RIPPON

❮ Previous
Next ❯

Citations

Jun 15, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G MedinaC Sola
Apr 20, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa S YoungLisa G Winston
Nov 17, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jinnethe ReyesCesar A Arias
Mar 16, 2005·Pharmacotherapy·Michael J Rybak, Kerry L LaPlante
Aug 1, 2015·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Rodrigo E MendesRobert K Flamm
Jan 6, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Eduardo Rodríguez-NoriegaEduardo Gotuzzo
Dec 24, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sabrina Di GregorioMarta Mollerach
Aug 31, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·A L R Z BerettaM L Moretti
Dec 1, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Paula Pena AmayaMarta Mollerach
Sep 14, 2018·Clinical Microbiology Reviews·Sahreena Lakhundi, Kunyan Zhang
Apr 3, 2010·Molecular Diagnosis & Therapy·Julianna Kurlenda, Mariusz Grinholc
Jul 26, 2011·Microbes and Infection·María Sol BarbagelataFernanda Buzzola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.